Inspire (INSP) Q2 2025 Earnings Call Transcript

Inspire Medical reported Q2 revenue of $217.1 million, up 11% year over year, but cut full-year 2025 revenue guidance to $900 million-$910 million from $940 million-$955 million and lowered EPS guidance to $0.40-$0.50 from $2.20-$2.30. Management blamed the revision on a slower-than-expected Inspire V rollout, Medicare billing delays until July 1, inventory destocking, and higher patient marketing spend, while noting $11.2 million of accelerated stock-comp expense and $1.7 million of legal fees. Gross margin held at 84% and adjusted EBITDA rose 14% to $44.1 million, but the quarter swung to a $3.6 million net loss versus $9.8 million of net income a year ago.

Analysis

The near-term issue is not demand destruction in the classic sense; it is a conversion bottleneck. Inspire is effectively carrying two operational drags at once: a workflow migration that slows case throughput and a billing transition that suppresses Medicare monetization until sites are fully trained and live. That makes the reset look temporary in shape but broad in impact, which is why the market may be underestimating how much of the FY25 shortfall is timing versus true end-demand.

The second-order dynamic is that Inspire V should improve the installed base economics once the friction clears. Removing the pressure-sensing lead and adding SleepSync reduces surgeon and facility hassle, which should disproportionately help high-volume centers and recruit marginal users back into the channel; that is more powerful than simple unit demand because it expands capacity per OR day. If management is right, 2026 should not just recover lost revenue, it should come with better operating leverage as the commercial machine reaccelerates off a lower-cost per case structure.

The contrarian risk is that the reset may be masking a structural shift in utilization patterns. If GLP-1 adoption keeps pushing patients to delay surgery longer, or if Medicare reimbursement economics remain psychologically less attractive even after billing is enabled, then the “temporary” slowdown could extend into a slower growth regime. In that case, the bigger risk isn’t 2025 EPS—it is a lower terminal growth rate because the addressable funnel is being throttled at the top while the company simultaneously spends more to reignite it.

Key Decisions for Investors

• Short-term: buy INSP Jan-2026 call spreads on weakness, sized for a 3-6 month catalyst window into full SleepSync completion and broader Medicare billing normalization; target a rebound if 2H data shows center conversion and utilization inflecting.
• Pair trade: long INSP / short a lower-quality medtech name with launch execution risk over the next 2 quarters; INSP has the cleaner path to step-function volume recovery once rollout friction clears, while the short leg should be a name with stretched launch expectations.
• For hedged longs: add INSP only after the next monthly channel check confirms center conversion progress, because the stock likely remains range-bound until evidence appears that Q3 is the trough and Q4 ramp is real.
• If already long INSP, consider monetizing upside via covered calls into the next earnings date; the setup is operationally improving but still depends on execution, making near-term multiple expansion vulnerable to any further rollout slippage.
• Avoid chasing the post-earnings selloff aggressively until reimbursement and implant-volume data show that the 20%+ productivity uplift is propagating beyond the limited-release cohort; that is the cleanest signal the thesis is expanding rather than isolated.